Login to Your Account



Genzyme Seeks Mozobil Nod in Lymphoma, Multiple Myeloma

By Donna Young


Wednesday, June 18, 2008
Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription